Patents by Inventor Hans-Jurgen Pfannkuche

Hans-Jurgen Pfannkuche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • New Oral Formulation
    Publication number: 20120071537
    Abstract: The present invention relates to a pharmaceutical composition, in particular to a composition for administering active agents which are poorly soluble in aqueous media, and/or which are acid sensitive.
    Type: Application
    Filed: November 23, 2011
    Publication date: March 22, 2012
    Inventors: Karel De Bruijn, Günter Engel, Hans-Jürgen Pfannkuche, Michael Thewissen, Christian Vitzling, Othmar Züger
  • Use of Mglur5 (Esp. Afq056) in Gi (Esp.Gerd)
    Publication number: 20080207749
    Abstract: The invention relates to the use of a compound acting as mGluR5 antagonist in the treatment, preventions and/or delay of progression of disorders of the gastrointestinal tract, disorders of the urinary tract and/or post-operative disorders and to the treatment, prevention and/or delay of progression of pain associated with these indications.
    Type: Application
    Filed: July 10, 2006
    Publication date: August 28, 2008
    Inventors: Marie-Laure Rouzade-Dominguez, Hans-Jurgen Pfannkuche, Fabrizio Gasparini
  • New Oral Formulation
    Publication number: 20080075773
    Abstract: The present invention relates to a pharmaceutical composition, in particular to a composition for administering active agents which are poorly soluble in aqueous media, and/or which are acid sensitive.
    Type: Application
    Filed: November 29, 2007
    Publication date: March 27, 2008
    Inventors: Karel De Bruijn, Gunter Engel, Hans-Jurgen Pfannkuche, Michael Thewissen, Christian Vitzling, Othmar Zuger
  • Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera
    Publication number: 20070293473
    Abstract: The use of a compound of formula I in free form or in the form of a pharmaceutically acceptable salt for the preparation of a medicament for the treatment of a functional motility disorder of the viscera.
    Type: Application
    Filed: August 23, 2007
    Publication date: December 20, 2007
    Inventors: John Fozard, Eckhard Weber, Hans-Jurgen Pfannkuche
  • Use of gaba-b receptor positive modulators in gastro-intestinal disorders
    Publication number: 20050245613
    Abstract: The invention relates to the use of a compound acting as positive allosteric modulator of GABAB receptors in the treatment of GERD, regurgitation, IBS, dyspepsia, postoperative complaints and conditions associated with visceral discomfort/pain.
    Type: Application
    Filed: April 23, 2003
    Publication date: November 3, 2005
    Inventor: Hans-Jurgen Pfannkuche
  • Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera
    Publication number: 20050203164
    Abstract: The use of a compound of formula I in free form or in the form of a pharmaceutically acceptable salt for the preparation of a medicament for the treatment of a functional motility disorder of the viscera.
    Type: Application
    Filed: February 7, 2003
    Publication date: September 15, 2005
    Inventors: John Fozard, Eckhard Weber, Hans-Jurgen Pfannkuche
  • Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
    Publication number: 20040092511
    Abstract: The present invention relates to a combination of a first agent including either a 5-HT4 receptor agonist or antagonist or a 5-HT3 receptor antagonist and a co-agent and pharmaceutical compositions and formulations containing the combination. The present invention also relates to a method of treating a gastrointestinal and abdominal viscera disorder by administering the pharmaceutical compositions to a patient. The pharmaceutical compositions may also be employed as laxatives, to prepare a patient for colonoscopy and to regulate and stabilize enterochromaffin cell secretory, pain and motility mechanisms, afferent fiber activity and GI and lower abdominal smooth muscle cells. The dosage is preferably oral and administration is preferably once or twice a day. The preferred first agent is tegaserod.
    Type: Application
    Filed: November 6, 2003
    Publication date: May 13, 2004
    Inventors: Stephan Anthony Billstein, Peter Dumovic, Nicola Franco, Mark Thomas Iwicki, Hans-Jurgen Pfannkuche, Edward Joseph Wilusz
  • Oral formulation
    Publication number: 20030236183
    Abstract: The present invention relates to a pharmaceutical composition, in particular to a composition for administering active agents which are poorly soluble in aqueous media, and/or which are acid sensitive.
    Type: Application
    Filed: July 15, 2003
    Publication date: December 25, 2003
    Inventors: Karel De Bruijn, Gunter Engel, Hans-Jurgen Pfannkuche, Michael Thewissen, Christian Vitzling, Othmar Zuger